688293.SH上海证券交易所 · 科创板 STAR
OPM Biosciences 奥浦迈
Biologics 生物制品
¥77.45−¥7.55 · −8.88%
Open 开盘
¥83.05
High 最高
¥83.29
Low 最低
¥77.45
Prev Close 昨收
¥85.00
Volume 成交量
702.3万股
Turnover 成交额
¥5.57亿
Mkt Cap 总市值
¥110亿
P/E 市盈率
85.9×
Recent Activity 近期动态All Filings 全部公告 →
27 significant filings since 29 May 2026: 7 on change of interest, 6 on equity incentive and 5 on major holder selling, and 4 other kinds. The latest, on 25 Sep 2026: 奥浦迈：关于持股5%以下特定股东减持股份计划公告. On 23 Jul 2026 the company said it expects net profit for the period ending 30 Jun 2026 to rise by 229.00% from the same period a year earlier.
自 29 May 2026 起有 27 份重大公告：change of interest 7 份、equity incentive 6 份、major holder selling 5 份，另有 4 类。最新一份（25 Sep 2026）：奥浦迈：关于持股5%以下特定股东减持股份计划公告。23 Jul 2026 公司预告截至 30 Jun 2026 的净利润较上年同期上升 229.00%。
40.0050.0060.0070.0080.00
Volume 成交量
1,137.7万
25 Jun17 Jul10 Aug02 Sep24 Sep
Overview 概览Deep Report 深度报告Financials 财务Valuation 估值Ownership 股东Analysts 券商Estimates 预测News 动态Events 事件Peers 同业
Against Its Own History 与自身历史比较
Price-to-Earnings Ratio
市盈率
The share price divided by earnings per share. A P/E of 20 means the price equals twenty years of the company’s current earnings per share.
股价除以每股收益。市盈率 20 倍，意味着股价相当于公司当前二十年的每股收益。 Lower is cheaper, but a low P/E often means the market expects profits to fall.
越低越便宜，但过低的市盈率往往意味着市场预期盈利将下滑。
股价除以每股收益。市盈率 20 倍，意味着股价相当于公司当前二十年的每股收益。 Lower is cheaper, but a low P/E often means the market expects profits to fall.
越低越便宜，但过低的市盈率往往意味着市场预期盈利将下滑。
85.9×
Median 中值 109.8× · Range 区间 43.9× to 411.5× · 16 periods 期
Price-to-Book Ratio
市净率
The share price divided by book value per share. Book value is what the company owns after debts, so below 1.0 the market values the business at less than its balance sheet.
股价除以每股净资产。净资产是公司扣除负债后的家底，低于 1 倍说明市场给公司的估值低于其账面价值。 It is useful for banks and asset-heavy industries and tells you little about software companies.
适用于银行和重资产行业，对软件公司参考意义不大。
股价除以每股净资产。净资产是公司扣除负债后的家底，低于 1 倍说明市场给公司的估值低于其账面价值。 It is useful for banks and asset-heavy industries and tells you little about software companies.
适用于银行和重资产行业，对软件公司参考意义不大。
3.51×
Median 中值 2.47× · Range 区间 1.69× to 4.67× · 16 periods 期
Period by Period 逐期
| Period 报告期 | Close at Period End 期末收盘 | TTM EPS 滚动每股收益 |
Price-to-Earnings Ratio
市盈率
The share price divided by earnings per share. A P/E of 20 means the price equals twenty years of the company’s current earnings per share. 股价除以每股收益。市盈率 20 倍，意味着股价相当于公司当前二十年的每股收益。 Lower is cheaper, but a low P/E often means the market expects profits to fall. 越低越便宜，但过低的市盈率往往意味着市场预期盈利将下滑。 | BPS 每股净资产 |
Price-to-Book Ratio
市净率
The share price divided by book value per share. Book value is what the company owns after debts, so below 1.0 the market values the business at less than its balance sheet. 股价除以每股净资产。净资产是公司扣除负债后的家底，低于 1 倍说明市场给公司的估值低于其账面价值。 It is useful for banks and asset-heavy industries and tells you little about software companies. 适用于银行和重资产行业，对软件公司参考意义不大。 |
|---|---|---|---|---|---|
| 30 Jun 2026 中报 | ¥41.69 | ¥0.95 | 43.9× | ¥22.10 | 1.89× |
| 31 Mar 2026 一季报 | ¥43.00 | ¥0.54 | 79.6× | ¥20.38 | 2.11× |
| 31 Dec 2025 年报 | ¥49.00 | ¥0.37 | 132.4× | ¥18.45 | 2.66× |
| 30 Sep 2025 三季报 | ¥64.22 | ¥0.39 | 164.7× | ¥18.51 | 3.47× |
| 30 Jun 2025 中报 | ¥45.01 | ¥0.31 | 145.2× | ¥18.62 | 2.42× |
| 31 Mar 2025 一季报 | ¥36.39 | ¥0.15 | 242.6× | ¥18.61 | 1.96× |
| 31 Dec 2024 年报 | ¥36.48 | ¥0.19 | 192.0× | ¥18.27 | 2.00× |
| 30 Sep 2024 三季报 | ¥33.70 | ¥0.33 | 102.1× | ¥18.31 | 1.84× |
| 30 Jun 2024 中报 | ¥31.27 | ¥0.35 | 89.3× | ¥18.53 | 1.69× |
| 31 Mar 2024 一季报 | ¥38.70 | ¥0.43 | 90.0× | ¥18.76 | 2.06× |
| 31 Dec 2023 年报 | ¥55.17 | ¥0.47 | 117.4× | ¥18.81 | 2.93× |
| 30 Sep 2023 三季报 | ¥49.38 | ¥0.12 | 411.5× | ¥18.80 | 2.63× |
| 30 Jun 2023 中报 | ¥47.67 | ¥0.50 | 95.3× | ¥18.95 | 2.52× |
| 31 Mar 2023 一季报 | ¥110.20 | ¥0.84 | 131.2× | ¥26.95 | 4.09× |
| 31 Dec 2022 年报 | ¥103.20 | ¥1.04 | 99.2× | ¥26.65 | 3.87× |
| 30 Sep 2022 三季报 | ¥123.12 | ¥1.53 | 80.5× | ¥26.37 | 4.67× |
Consensus Forward EPS 机构预测每股收益
No broker forecasts for this company yet 暂无机构预测
Not Computed 未计算
- Dividend Yield 股息率
- Free Cash Flow 自由现金流
- EV/EBITDA